Novye preparaty, vosstanavlivayushchie immunnyy kontrol' nad opukhol'yu v terapii patsientov s metastaticheskoy melanomoy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Treatment of disseminated melanoma many years remained challenging. Standard chemotherapy had no fundamentally effect on overall survival of patients. Given the high immunogenicity of the tumor, immunotherapy of melanoma was always the center of attention of researchers. However, the first real success of immunotherapy for metastatic melanoma is associated with the emergence of a new generation of immunotherapeutic drugs - inhibitors of regulatory molecules of key stages of the immune response. The article describes the main drugs of this group, and the latest results from clinical studies conducted in disseminated melanoma are presented.

Full Text

Restricted Access

References

  1. Atkins M., Kunkel L., Sznol M., Rosenberg S. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 2000;6(suppl. 1):S11-S14.
  2. Melero I., Grimaldi A., Perez-Gracia J., Ascierto P. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin. Cancer Res. 2013; 19:997-1008.
  3. Wolchok J. How recent advances in immunotherapy are changing the standart of care in patients with metastatic melanoma. Ann. Oncol. 2012;23(suppl. 8):15-21.
  4. O'Day S.J., Maio M., Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with previously treated, advanced melanoma: a multicenter singlearm phase II study. Ann. Oncol. 2010;21: 1712-17.
  5. Weber J., Thompson J.A., Hamid O., et al. A randomized, double-blind, placebo controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 2009;15:5591-98.
  6. Hodi F., O'Day S., McDermott D., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010;363:711-23.
  7. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011;364:2517-26.
  8. Di Giacomo A., Grimaldi A., Ascierto P., et al. Correlation between efficacy and toxicity in patients with pretreated advanced melanoma treated within the Italian cohort of the ipilimumab expanded access program. J. Clin Oncol. 2013;31(suppl.):Abstract 9070
  9. Kaehler K., Piel S., et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, and their management. Seminars Oncology. 2010;37:485-98.
  10. Scarlati G., Fusciello C., Perri F., et al. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Oncol. Targets Ther. 2014;7:203-09.
  11. Schadendorf D., Hodi S., Robert C., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur. J. Cancer. 2013;49(suppl. 3):Abstarct LBA24.
  12. Eggermont A., Chiarion-Sileni V., Grob J., et al. Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. J. Clin. Oncol. 2014;32(suppl.):Abstract LBA 9008.
  13. Keir M, Butte M., Freeman G., Sharpe A. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008;26:677-704.
  14. Topalian S., Hodi S., Brahmer J., et.al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012;366:2443-53.
  15. Hamid O., Rober C., Daud A., et al. Safety and tumor responses with labrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013; 369:134-44.
  16. Weber J., D'Angelo S., Gutzmer R., et al. A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. ESMO. 2014:abstract LBA3.
  17. Wolchok J., Kluger H., Callahan M., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013;369:122-33.
  18. Robert C., Ribas A., Wolchok J., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109-17.
  19. Ribas A., Hodi S., Kefford R., at el. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J. Clin. Oncol. 2014; 32(5S).
  20. Hamid O., Sosman J., Lawrence D., et al. Clinical activity, safety and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma. J. Clin. Oncol. 2013;31:Abstract 9010.
  21. Brahmer J., Tykodi S., Chow L., et al. Safery and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2013;369:122-33.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies